Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-23T15:20:46.475Z Has data issue: false hasContentIssue false
  • English
  • Français

Tardive dyskinesia – how is it prevented and treated?

Published online by Cambridge University Press:  02 January 2018

Denise Duncan ,
Harry McConnell  and
David Taylor
Denise Duncan*
Affiliation:
Maudsley Hospital
Harry McConnell
Affiliation:
Institute of Psychiatry
David Taylor
Affiliation:
Maudsley Hospital Denmark Hill London SE5 8AZ
*
∗Correspondence
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Tardive dyskinesia (TD), literally meaning a late occurring, abnormal movement disorder, was first described by Schonecker in 1957, about five years after the discovery of chlorpromazine (cited in Kane, 1992). TD generally occurs after long-term antipsychotic therapy: Kane et al (1984) reported that the incidence was increased with each subsequent year of exposure to antipsychotics, starting with an incidence of 5% after one year of exposure and increasing by 5% each subsequent year. Certainly, the prevalence of TD has increased over the last 20 years, probably as the result of more patients being exposed to antipsychotics for longer periods.

Type
Drug Information Quarterly
Information
Psychiatric Bulletin , Volume 21 , Issue 7 , July 1997 , pp. 422 - 425
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1997 The Royal College of Psychiatrists

References

Bazire, S. (ed.) (1996) Psychotropic Drug Directory 1996. Dinton, Wiltshire: Mark Allen Publishing.Google Scholar
Dabiri, L. M., Pasta, D., Darby, J. K., et al (1994) Effectiveness of Vitamin E for treatment of long-term tardive dyskinesia. American Journal of Psychiatry, 151, 925–926.Google ScholarPubMed
Egan, M. F., Hyde, T. M., Albers, G. W., et al (1992) Treatment of tardive dyskinesia with Vitamin E. American Journal of Psychiatry, 149, 773–777.Google ScholarPubMed
Elkashef, A. M., Ruskin, P. E., Bacher, N., et al (1990) Vitamin E in the treatment of tardive dyskinesia. American Journal of Psychiatry, 147, 505–506.Google ScholarPubMed
Jeste, D. V. & Caligiuri, M. P. (1993) Tardive dyskinesia. Schizophrenia Bulletin, 19, 303–315.CrossRefGoogle ScholarPubMed
Kane, J. M. (1992) Tardive dyskinesia. In Movement Disorders in Neurology and Neuropsychiatry (eds Joseph, A. B. & Young, R. R.) pp. 33–39. Oxford: Blackwell Scientific.Google Scholar
Kane, J. M., Woerner, M., Weinhold, P., et al (1984) Incidence of tardive dyskinesia: five year data from a prospective study. Psychopharmacology Bulletin, 20, 387. (Cited in Miyasaki & Lang, 1995).Google ScholarPubMed
Lieberman, J. A., Saltz, B. L., Johns, C. A., et al (1991) The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry, 158, 503–510.CrossRefGoogle ScholarPubMed
Lohr, J. B., Cadet, J. L., Lohr, M. A., et al (1987) Alphatocopherol in tardive dyskinesia. Lancet, 1, 913–914.CrossRefGoogle ScholarPubMed
Lohr, J. B., & Jeste, D. V. (1992) Neuroleptic-induced movement disorders: tardive dyskinesia and other tardive syndromes. In Psychiatry, Vol 3. (ed. Michels, R.), pp. 1–17. Philadelphia: J. B. Lippincott.Google Scholar
Lohr, J. B. & Caligiuri, M. (1996) A double-blind placebo-controlled study of Vitamin E treatment of tardive dyskinesia. Journal of Clinical Psychiatry, 57, 167–173.Google ScholarPubMed
Miller, L. G. & Jankovic, J. (1992) Drug-induced movement disorders: an overview. In Movement Disorders in Neurology and Neuropsychiatry (eds Joseph, A. B. & Young, R. R.), pp. 5–32. Oxford: Blackwell Scientific.Google Scholar
Miyasaki, J. M. & Lang, A. E. (1995) Treatment of drug-induced movement disorders. In Treatment of Movement Disorders (ed. Kurlan, R.), pp. 429–474. Philadelphia: J. B. Lippincott.Google Scholar
Shapleske, J., McKay, A. P. & McKenna, P. J. (1996) Successful treatment of tardive dystonia with clozapine and clonazepam. British Journal of Psychiatry, 168, 516–518.CrossRefGoogle ScholarPubMed
Thaker, G. K., Nguyen, J. A., Strauss, M. E., et al (1990) Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. American Journal of Psychiatry, 147, 445–451.Google ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.